MiR-10a-5p: A Promising Biomarker for Early Diagnosis and Prognosis Evaluation of Bladder Cancer

References

• Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):177–189. doi:10.1016/j.hoc.2014.10.00125836927
   PubMed Web of Science ®Google Scholar
• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: a Global Overview and Recent Trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.01027370177
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76(5):639–657. doi:10.1016/j.eururo.2019.08.01631443960
   PubMed Web of Science ®Google Scholar
• Moschini M, D’Andrea D, Korn S, et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol. 2017;14(11):651–668. doi:10.1038/nrurol.2017.12528895563
   PubMed Web of Science ®Google Scholar
• DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: diagnosis and Treatment. Am Fam Physician. 2017;96(8):507–514.29094888
   PubMed Web of Science ®Google Scholar
• Fankhauser CD, Mostafid H. Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. Curr Opin Urol. 2018;28(1):88–92. doi:10.1097/MOU.000000000000045229211694
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W. Molecular Subtypes of Bladder Cancer. Curr Oncol Rep. 2018;20(10):77. doi:10.1007/s11912-018-0727-530128829
   PubMed Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111. doi:10.1038/nrurol.2017.17929133939
   PubMed Web of Science ®Google Scholar
• Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016;34(12):556–565. doi:10.1016/j.urolonc.2016.10.00627836246
   PubMed Web of Science ®Google Scholar
• Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: present and future. Med Clin (Barc). 2017;149(10):449–455. doi:10.1016/j.medcli.2017.06.00928736063
   PubMed Web of Science ®Google Scholar
• Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15(5):429. doi:10.2174/13892010150514082816133525189575
   PubMed Web of Science ®Google Scholar
• Qadir MI, Faheem A. miRNA: a Diagnostic and Therapeutic Tool for Pancreatic Cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204. doi:10.1615/CritRevEukaryotGeneExpr.201701949429199604
   PubMed Web of Science ®Google Scholar
• Sun Z, Shi K, Yang S, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147. doi:10.1186/s12943-018-0897-730309355
   PubMed Web of Science ®Google Scholar
• Barbato S, Solaini G, Fabbri M. MicroRNAs in Oncogenesis and Tumor Suppression. Int Rev Cell Mol Biol. 2017;333:229–268.28729026
   PubMed Web of Science ®Google Scholar
• Wieczorek E, Reszka E. mRNA, microRNA and lncRNA as novel bladder tumor markers. Clin Chim Acta. 2018;477:141–153. doi:10.1016/j.cca.2017.12.00929224950
   PubMed Web of Science ®Google Scholar
• Cochetti G, Vermandois JA, Maulà V, et al. Role of miRNAs in prostate cancer: do we really know everything? Urol Oncol. 2020;38(7):623–635. doi:10.1016/j.urolonc.2020.03.00732284256
   PubMed Web of Science ®Google Scholar
• Xiong G, Huang H, Feng M, et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2018;37(1):76. doi:10.1186/s13046-018-0739-x29615098
   PubMed Web of Science ®Google Scholar
• Zhi Y, Xie X, Wang R, et al. Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia. Int J Hematol. 2015;102(3):296–303. doi:10.1007/s12185-015-1829-626134365
   PubMed Web of Science ®Google Scholar
• Guo L, Li Y, Zhao C, et al. RECQL4, Negatively Regulated by miR-10a-5p, Facilitates Cell Proliferation and Invasion via MAFB in Ovarian Cancer. Front Oncol. 2020;10:524128. doi:10.3389/fonc.2020.52412833014878
   PubMed Web of Science ®Google Scholar
• Bao M, Pan S, Yang W, Chen S, Shan Y, Shi H. Serum miR-10a-5p and miR-196a-5p as non-invasive biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol. 2018;11(2):773–780.31938164
   PubMed Web of Science ®Google Scholar
• Arai T, Okato A, Kojima S, et al. Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma. Cancer Sci. 2017;108(10):2088–2101. doi:10.1111/cas.1333128746769
   PubMed Web of Science ®Google Scholar
• Zhai L, Li Y, Lan X, Ai L. MicroRNA-10a-5p suppresses cancer proliferation and division in human cervical cancer by targeting BDNF. Exp Ther Med. 2017;14(6):6147–6151.29285171
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Usuba W, Urabe F, Yamamoto Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 2019;110(1):408–419. doi:10.1111/cas.1385630382619
   PubMed Web of Science ®Google Scholar
• Lin GB, Zhang CM, Chen XY, et al. Identification of circulating miRNAs as novel prognostic biomarkers for bladder cancer. Mathematical Biosci Eng. 2019;17(1):834–844. doi:10.3934/mbe.2020044
   PubMed Web of Science ®Google Scholar
• Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11(7):2625–2636. doi:10.1158/1078-0432.CCR-04-198815814643
   PubMed Web of Science ®Google Scholar
• Shi HB, Yu JX, Yu JX, et al. Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles. World J Surg Oncol. 2017;15(1):147. doi:10.1186/s12957-017-1201-928774300
   PubMed Web of Science ®Google Scholar
• Tölle A, Blobel CC, Jung K. Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017. Biomark Med. 2018;12(6):667–676. doi:10.2217/bmm-2017-039229896971
   PubMed Web of Science ®Google Scholar